Opthea Limited ( (AU:OPT) ) has provided an update.
Opthea Limited announced the publication of Phase 2b trial data for sozinibercept in a peer-reviewed journal, highlighting its superior efficacy in treating wet AMD when combined with ranibizumab. The trial showed significant visual acuity improvements and anatomical benefits for patients with certain lesion types, informing the design of Opthea’s Phase 3 clinical program. This advancement positions Opthea to potentially offer a groundbreaking treatment option for wet AMD, addressing a significant unmet medical need and impacting the company’s future market positioning.
More about Opthea Limited
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening eye diseases, such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Their lead product candidate, sozinibercept, is a first-in-class VEGF-C/D ‘trap’ inhibitor being evaluated in combination with standard anti-VEGF-A therapies to improve vision outcomes for wet AMD patients.
YTD Price Performance: 9.09%
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $733.6M
See more insights into OPT stock on TipRanks’ Stock Analysis page.